InfuSystem (NYSE:INFU) Upgraded at StockNews.com

InfuSystem (NYSE:INFU - Get Free Report) was upgraded by investment analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research report issued on Friday.

Separately, B. Riley assumed coverage on InfuSystem in a report on Thursday, September 26th. They set a "buy" rating and a $13.00 price target for the company.

InfuSystem Stock Up 6.4 %

NYSE:INFU traded up $0.47 during trading hours on Friday, reaching $7.81. The company had a trading volume of 102,491 shares, compared to its average volume of 57,218. The firm has a market cap of $166.51 million, a price-to-earnings ratio of 781.78 and a beta of 1.45. The business has a 50-day simple moving average of $6.56. InfuSystem has a one year low of $5.74 and a one year high of $10.99. The company has a quick ratio of 1.64, a current ratio of 2.07 and a debt-to-equity ratio of 0.64.

InfuSystem (NYSE:INFU - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). InfuSystem had a net margin of 0.28% and a return on equity of 0.70%. The firm had revenue of $33.70 million for the quarter. As a group, sell-side analysts expect that InfuSystem will post 0.17 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Williams & Novak LLC acquired a new stake in shares of InfuSystem during the 3rd quarter worth approximately $70,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in InfuSystem during the 3rd quarter worth $87,000. Rhumbline Advisers raised its position in shares of InfuSystem by 13.8% during the 2nd quarter. Rhumbline Advisers now owns 17,658 shares of the company's stock valued at $121,000 after acquiring an additional 2,145 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of InfuSystem in the 2nd quarter valued at $131,000. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of InfuSystem by 52.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company's stock worth $178,000 after purchasing an additional 8,917 shares during the last quarter. Institutional investors and hedge funds own 71.13% of the company's stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.